<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9717249</journal-id>
<journal-id journal-id-type="pubmed-jr-id">36321</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Protoc Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Protoc Pharmacol</journal-id>
<journal-title-group>
<journal-title>Current protocols in pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1934-8282</issn>
<issn pub-type="epub">1934-8290</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29927058</article-id>
<article-id pub-id-type="pmc">6019607</article-id>
<article-id pub-id-type="doi">10.1002/cpph.41</article-id>
<article-id pub-id-type="manuscript">NIHMS949740</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Measuring Histone Deacetylase Inhibition in the Brain</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Reddy</surname>
<given-names>Doodipala Samba</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Xin</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Golub</surname>
<given-names>Victoria M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dashwood</surname>
<given-names>W. Mohaiza</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dashwood</surname>
<given-names>Roderick H.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Neuroscience and Experimental Therapeutics, Texas
A&amp;M University Health Science Center, College of Medicine, Bryan, TX
77807</aff>
<aff id="A2">
<label>2</label>Center for Epigenetics &amp; Disease Prevention, Texas
A&amp;M University Health Science Center, College of Medicine, Houston, TX
77030</aff>
<author-notes>
<corresp id="FN1">*<bold><italic>Correspondence to:</italic></bold> D. Samba
Reddy, Department of Neuroscience and Experimental Therapeutics, Texas
A&amp;M University Health Science Center, College of Medicine, 8447
Riverside Parkway, Bryan, TX 77807, USA,
<email>reddy@medicine.tamhsc.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p><bold>Conflict of Interest</bold>. The authors declare no competing financial
interests.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>16</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>07</day>
<month>6</month>
<year>2019</year>
</pub-date>
<volume>81</volume>
<issue>1</issue>
<fpage>e41</fpage>
<lpage>e41</lpage>
<!--elocation-id from pubmed: 10.1002/cpph.41-->
<abstract>
<p id="P1">Histone deacetylases (HDACs) represent a family of enzymes that are
targets for epigenetic modulation of genomic activity that may be beneficial in
the treatment of many diseases, including cancer and CNS disorders. In animal
models, HDAC inhibitors have neuroprotective, antiepileptogenic, and
antidepressant effects. Assaying HDAC activity provides a robust method for
identifying HDAC inhibitors and for assessing their effects under various
physiological conditions or after pathological insults. In this unit, a simple
and sensitive assay for measuring HDAC activity is described. HDAC activity in
tissue lysates can be assessed fluorometrically using a Boc-Lys(Ac) HDAC
activity kit. HDACs catalyze the deacetylation of the substrate,
Boc-Lys(Ac)-AMC. Addition of a trypsin-containing developer converts the
deacetylated product to a quantifiable fluorophore that can be used both as a
screening method to identify putative HDAC inhibitors. and to assess the effects
of these inhibitors on tissue and animal epigenetic-modulated phenotypes.</p>
</abstract>
<kwd-group>
<kwd>HDAC</kwd>
<kwd>Epigenetic</kwd>
<kwd>HDAC substrate</kwd>
<kwd>Sodium Butyrate</kwd>
<kwd>Trichostatin-A</kwd>
<kwd>nuclear protein</kwd>
<kwd>fluorophore</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>